Breaking News Instant updates and real-time market news.

INTU

Intuit

$276.05

-0.29 (-0.10%)

06:57
08/23/19
08/23
06:57
08/23/19
06:57

Intuit price target raised to $305 from $300 at KeyBanc

KeyBanc analyst Josh Beck raised his price target for Intuit to $305 from $300 and maintained an Overweight rating following the company's quarterly results, saying Intuit beat and raised the outyear driven by strength in the QuickBooks franchise where payments volume grew 40% and online payroll grew 35%. Beck tells investors in a research note that he remains bullish on FinTech, Intuit's consumer ecosystem and its international prospects, where he sees a substantial growth runway.

  • 27

    Oct

INTU Intuit
$276.05

-0.29 (-0.10%)

05/24/19
LEHM
05/24/19
NO CHANGE
Target $237
LEHM
Equal Weight
Intuit price target raised to $237 from $225 at Barclays
Barclays analyst Raimo Lenschow raised his price target for Intuit to $237 from $225 saying investors, post the company's fiscal Q3 results, should have a better understanding of its tax season. Intuit achieved better pricing on the high end with its "Live" product and increased its focus on Free, which somewhat limited upside, Lenschow tells investors in a research note. He keeps an Equal Weight rating on the shares.
05/24/19
JEFF
05/24/19
NO CHANGE
Target $300
JEFF
Buy
Intuit price target raised to $300 from $272 at Jefferies
Jefferies analyst Brent Thill raised his price target for Intuit to $300 from $272 saying the company posted a beat in fiscal Q3 despite the Consumer segment coming in slightly below investor expectations. The analyst views Intuit's tax season as "solid" and says the stock "remains a favorite large cap story." He keeps a Buy rating on the shares.
07/10/19
STFL
07/10/19
NO CHANGE
Target $290
STFL
Buy
Intuit price target raised to $290 from $258 at Stifel
Stifel analyst Brad Reback raised his price target on Intuit shares to $290 from $258 after hosting meetings with the company's senior management team. He believes investors are just beginning to appreciate the value Intuit can generate from its tightly integrated platform approach and thinks this strategy and the company's "vast trove of customer data" will make it increasingly difficult for the competition to close the gap, said Reback, who keeps a Buy rating on the stock.
08/23/19
DBAB
08/23/19
NO CHANGE
Target $315
DBAB
Buy
Intuit price target raised to $315 from $290 at Deutsche Bank
Deutsche Bank analyst Michael Turrin raised his price target on Intuit to $315 and kept his Buy rating after its "solid" Q4 results and above-consensus FY20 guidance. The analyst notes that the outlook calls for small business segment growth of 12%-14% - above 9%-11% initial outlook last year. Turrin also states that the 9%-11% consumer segment growth outlook was maintained with the forecast made last year and suggests the management's "continued confidence" in Intuit's share gains and average revenue per user, or ARPU, expansion.

TODAY'S FREE FLY STORIES

OSMT

Osmotica Pharmaceuticals

$3.84

0.15 (4.07%)

06:51
09/17/19
09/17
06:51
09/17/19
06:51
Hot Stocks
Osmotica subsidiary submits NDA to FDA for RVL-1201 »

Vertical Pharmaceuticals,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EAST

Eastside Distilling

$4.97

-0.03 (-0.60%)

06:51
09/17/19
09/17
06:51
09/17/19
06:51
Conference/Events
Eastside Distilling to host conference call »

Conference call to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Sep

ADS

Alliance Data

$132.88

-1.11 (-0.83%)

, SBH

Sally Beauty

$14.47

-0.12 (-0.82%)

06:49
09/17/19
09/17
06:49
09/17/19
06:49
Hot Stocks
Alliance Data signs agreement to provide credit card services for Sally Beauty »

Alliance Data (ADS) has…

ADS

Alliance Data

$132.88

-1.11 (-0.83%)

SBH

Sally Beauty

$14.47

-0.12 (-0.82%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Sep

  • 18

    Sep

  • 23

    Sep

  • 13

    Nov

  • 03

    Dec

KAMN

Kaman

$63.22

0.55 (0.88%)

06:49
09/17/19
09/17
06:49
09/17/19
06:49
Hot Stocks
Kaman awarded $42M order of Joint Programmable Fuzes »

Kaman announced that it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ZYME

Zymeworks

$25.84

0.19 (0.74%)

06:49
09/17/19
09/17
06:49
09/17/19
06:49
Hot Stocks
Zymeworks names Lota Zoth as board Chair, voluntarily delists from TSX »

Zymeworks announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Sep

SBH

Sally Beauty

$14.47

-0.12 (-0.82%)

, ADS

Alliance Data

$132.88

-1.11 (-0.83%)

06:47
09/17/19
09/17
06:47
09/17/19
06:47
Hot Stocks
Sally Beauty signs agreement with Alliance Data's card services business »

Sally Beauty Holdings…

SBH

Sally Beauty

$14.47

-0.12 (-0.82%)

ADS

Alliance Data

$132.88

-1.11 (-0.83%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Sep

  • 18

    Sep

  • 23

    Sep

  • 13

    Nov

  • 03

    Dec

MRK

Merck

$82.01

-0.6 (-0.73%)

06:47
09/17/19
09/17
06:47
09/17/19
06:47
Hot Stocks
Merck: FDA accepts BLA, grants priority review for investigational Ebola vaccine »

Merck announced that the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Sep

  • 20

    Sep

  • 24

    Sep

  • 27

    Sep

  • 02

    Oct

  • 03

    Oct

  • 29

    Oct

XLRN

Acceleron

$44.67

0.75 (1.71%)

06:43
09/17/19
09/17
06:43
09/17/19
06:43
Recommendations
Acceleron analyst commentary  »

Acceleron should be…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

  • 17

    Oct

  • 04

    Dec

  • 04

    Apr

CBMG

Cellular Biomedicine

$14.75

-0.16 (-1.07%)

06:43
09/17/19
09/17
06:43
09/17/19
06:43
Initiation
Cellular Biomedicine initiated  »

Cellular Biomedicine…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EGOV

NIC Inc.

$21.79

0.05 (0.23%)

06:40
09/17/19
09/17
06:40
09/17/19
06:40
Downgrade
NIC Inc. rating change  »

NIC Inc. downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

SPLK

Splunk

$114.87

1.19 (1.05%)

06:39
09/17/19
09/17
06:39
09/17/19
06:39
Upgrade
JPMorgan upgrades Splunk to Overweight after 19% selloff since late July »

JPMorgan analyst Mark…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Oct

OLN

Olin

$19.27

0.46 (2.45%)

06:38
09/17/19
09/17
06:38
09/17/19
06:38
Conference/Events
Olin management to meet with SunTrust »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Sep

  • 19

    Sep

  • 23

    Sep

CBMG

Cellular Biomedicine

$14.75

-0.16 (-1.07%)

06:38
09/17/19
09/17
06:38
09/17/19
06:38
Initiation
Cellular Biomedicine initiated  »

Cellular Biomedicine…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AXNX

Axonics

$30.13

-0.77 (-2.49%)

06:37
09/17/19
09/17
06:37
09/17/19
06:37
Initiation
Axonics initiated  »

Axonics initiated with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HXGBY

Hexagon AB

$0.00

(0.00%)

06:36
09/17/19
09/17
06:36
09/17/19
06:36
Conference/Events
Hexagon AB management to meet with RBC Capital »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Sep

  • 19

    Sep

APOG

Apogee Enterprises

$41.18

-0.38 (-0.91%)

06:34
09/17/19
09/17
06:34
09/17/19
06:34
Earnings
Apogee Enterprises reaffirms FY20 EPS view $3.00-$3.20, consensus $3.05 »

Reaffirms FY20 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Sep

  • 18

    Sep

  • 23

    Sep

MDGL

Madrigal Pharmaceuticals

$99.50

4.89 (5.17%)

06:34
09/17/19
09/17
06:34
09/17/19
06:34
Recommendations
Madrigal Pharmaceuticals analyst commentary  »

Madrigal Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SFTBF

SoftBank

$0.00

(0.00%)

, UBER

Uber

$34.42

1.18 (3.55%)

06:32
09/17/19
09/17
06:32
09/17/19
06:32
Periodicals
SoftBank backers consider slashing committments to Vision Fund, Bloomberg says »

The biggest backers of…

SFTBF

SoftBank

$0.00

(0.00%)

UBER

Uber

$34.42

1.18 (3.55%)

WE

We Company

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SSI

Stage Stores

$0.85

0.0298 (3.63%)

06:32
09/17/19
09/17
06:32
09/17/19
06:32
Hot Stocks
Stage Stores announces plans to convert substantially all stores to off-price »

Stage Stores announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

APOG

Apogee Enterprises

$41.18

-0.38 (-0.91%)

06:31
09/17/19
09/17
06:31
09/17/19
06:31
Earnings
Apogee Enterprises reports Q2 EPS 72, consensus 64c »

Reports Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Sep

  • 18

    Sep

  • 23

    Sep

IAC

IAC

$229.23

1.71 (0.75%)

06:30
09/17/19
09/17
06:30
09/17/19
06:30
Initiation
IAC initiated  »

IAC initiated with a Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Oct

AMRN

Amarin

$17.26

0.55 (3.29%)

, MDCO

The Medicines Co.

$48.74

0.99 (2.07%)

06:29
09/17/19
09/17
06:29
09/17/19
06:29
Recommendations
Citi puts Amarin and Sarepta on top five SMid cap biotech pick list »

Citi analyst Joel Beatty…

AMRN

Amarin

$17.26

0.55 (3.29%)

MDCO

The Medicines Co.

$48.74

0.99 (2.07%)

NERV

Minerva

$8.12

0.12 (1.50%)

SRPT

Sarepta

$87.02

1.01 (1.17%)

ELOX

Eloxx Pharmaceuticals

$6.45

0.1 (1.57%)

NGM

NGM Biopharmaceuticals

$15.85

-0.15 (-0.94%)

PTCT

PTC Therapeutics

$42.99

0.16 (0.37%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Sep

MRVL

Marvell

$25.39

-0.46 (-1.78%)

06:28
09/17/19
09/17
06:28
09/17/19
06:28
Hot Stocks
SEC says Marvell Technology to pay $5.5M to settle disclosure-related charges »

The Securities and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ANGI

Angi Homeservices

$7.91

-0.075 (-0.94%)

, GOOG

Alphabet

$1,231.36

-8.24 (-0.66%)

06:28
09/17/19
09/17
06:28
09/17/19
06:28
Initiation
Angi Homeservices, Alphabet, Alphabet Class A initiated  »

Angi Homeservices…

ANGI

Angi Homeservices

$7.91

-0.075 (-0.94%)

GOOG

Alphabet

$1,231.36

-8.24 (-0.66%)

GOOGL

Alphabet Class A

$1,231.45

-8.68 (-0.70%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Sep

  • 27

    Oct

MTCH

Match Group

$76.70

1.74 (2.32%)

06:26
09/17/19
09/17
06:26
09/17/19
06:26
Initiation
Match Group initiated  »

Match Group initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.